Draig Therapeutics featured prominently this week with new clinical and investor-facing updates centered on its lead candidate DT-101. The company plans to present first-in-human Phase 1 data for the novel AMPA receptor positive allosteric modulator at the American Society of Clinical Psychopharmacology Annual Meeting in Miami in May 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The upcoming presentations include an oral session on May 26, 2026, followed by two poster presentations on May 28, 2026. Draig Therapeutics has highlighted favorable tolerability data and functional biomarker findings from the trial, signaling continued progress in early-stage development for its central nervous system program.
The focus on safety and biomarker readouts at this stage suggests the company is working to demonstrate a de-risked profile that could support advancement into later-phase studies. Multiple scientific touchpoints at a major psychopharmacology meeting also provide increased visibility among clinicians and researchers in neuropsychiatry.
Draig Therapeutics is using the conference to encourage engagement with clinicians, researchers, and potential business development partners. While the company has not yet released detailed numerical results, the emphasis on tolerability and functional biomarkers may be important for shaping future partnering and financing discussions around DT-101.
Separately, CEO and President Ivana Magovcevic-Liebisch is scheduled to participate in a C-suite session at the Convergence Forum, alongside leaders from Aitia, Xilio Therapeutics, Inc., and Atlas Venture. The off-the-record event underscores Draig’s efforts to deepen relationships with influential biotech and venture capital stakeholders.
Although the Convergence Forum appearance does not include new pipeline or financial disclosures, it reinforces the company’s strategic positioning within the sector. Overall, the week for Draig Therapeutics combined advancing clinical visibility for DT-101 with higher-profile executive networking, supporting its long-term business development and partnering prospects.